Sentia is poised to be the world leader in the development of novel peptide therapeutics to cure stress-related diseases.
Sentia seeks to bring to fruition 40 years of academic research to achieve translational drug candidacy, by developing drugs that block the action of corticotropin releasing factor (CRF) and urocortins, the main mediators of the body’s response to stress. Our mission is to manage, treat and cure stress-related disease. Whereas the majority of diseases are presently treated for their symptoms, the underlying role of stress has long been ignored. Often chronic stress results in important physiological mechanisms becoming imbalanced, leading to initiation or exacerbation of multiple diseases. Sentia will seek to harmonize and rebalance the physiology by using a new generation of drug candidates called astressins that have high efficacy and sustained effects.